In the first half of 2026, Eyebright Medical recorded total operating revenue of RMB 933 million, representing an 18.57% year-on-year increase. Net profit attributable to the parent company amounted to RMB 177 million. Overseas revenue reached RMB 96 million, up 123.21% year-on-year.

By business segment, intraocular lenses contributed RMB 306 million, contact lenses generated RMB 281 million, sports medicine contributed RMB 94 million, orthokeratology (corneal reshaping) lenses recorded RMB 124 million, and other product lines (including myopia management frames, lens care system, surgical blades, and viscoelastic agents) totaled RMB 97 million.